Completed OBSERVATIONAL NCT00492882

Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome (SOPK)

Dynamic Changes in the Serum Anti-Müllerian Hormone Level During Low-Dose recFSH Administration Further Support Its Role in the Anovulation of Polycystic Ovary Syndrome

Sponsor: Organon

Conditions Anovulation

Interventions usual administration of exogenous recombinant FSH

Updated 6 times since 2017 Last updated: Jun 26, 2007 Started: Nov 30, 2003 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Anovulation and is currently completed. Organon leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: PHASE4 → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon
University Hospital, Lille

Data source: University Hospital, Lille

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France